Tab Course of therapy: 7 days (may range from 5-10 days).
Adult & childn ≥40 kg Acute tonsillitis & pharyngitis, acute bacterial sinusitis, cystitis, pyelonephritis, uncomplicated skin & soft tissue infections 250 mg bd.
Acute otitis media, acute exacerbation of chronic bronchitis 500 mg bd.
Lyme disease 500 mg bd for 14 days (range of 10-21 days),
<40 kg Acute tonsillitis & pharyngitis, acute bacterial sinusitis 10 mg/kg bd to max: 125 mg bd.
Pyelonephritis 15 mg/kg bd to max: 250 mg bd for 10-14 days.
Cystitis, uncomplicated skin & soft tissue infections 15 mg/kg bd to max: 250 mg bd.
Lyme disease 15 mg/kg bd to a max: 250 mg bd for 14 days (10-21 days),
≥2 yr & <40 kg Otitis media or more severe infections 15 mg/kg bd to max: 250 mg bd.
Renal impairment CrCl ≥30 mL/min/1.73 m2 Standard dose of 125-500 mg bd,
10-29 mL/min/1.73 m2 Standard dose every 24 hr,
<10 mL/min/1.73 m2 Standard dose every 48 hr,
haemodialysis Further standard individual dose at end of each dialysis.
Inj Adult & childn ≥40 kg Community acquired pneumonia, acute exacerbation of chronic bronchitis, soft-tissue infection (eg, cellulitis, erysipelas & wound infections), intraabdominal infections 750 mg every 8 hr IV or IM.
Complicated UTI including pyelonephritis 1.5 g every 8 hr IV or IM.
Severe infections 750 mg every 6 hr IV or 1.5 g every 8 hr IV.
Surgical prophylaxis for GI, gynaecological surgery (including caesarean section) & orthopaedic operations 1.5 g w/ induction of anaesth. May be supplemented w/ 2 doses of 750 mg IM after 8 & 16 hr.
Surgical prophylaxis for CV & oesphageal operations 1.5 g w/ induction of anaesth followed by 750 mg IM every 8 hr for further 24 hr,
<40 kg & infant & toddler >3 wk Community acquired pneumonia, complicated UTI including pyelonephritis, soft-tissue infection (eg, cellulitis, erysipelas & wound infections) & intra-abdominal infections 30-100 mg/kg daily IV as 3 or 4 divided doses. A 60 mg/kg/day dose is appropriate for most infections,
infant (birth to 3 wk) Community acquired pneumonia, complicated UTI including pyelonephritis, soft-tissue infection (eg, cellulitis, erysipelas & wound infections) & intra-abdominal infections 30-100 mg/kg/day IV as 2 or 3 divided doses.
Renal impairment CrCl >20 mL/min/1.73 m2 Standard dose of 750 mg-1.5 g tds,
10-20 mL/min/1.73 m2 750 mg bd,
<10 mL/min/1.73 m2 750 mg once daily,
haemodialysis Further 750 mg IV or IM at end of each dialysis. Can be incorporated into peritoneal dialysis fluid (usually 250 mg for every 2 L),
renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units 750 mg bd.